Blog

Jan 17, 2014

BRIC-a-BRAC

1. On December 16, 2013, Columbia's National Institute of Food and Drug Monitoring (INVIMA) announced the approval of Remsima (infliximab) for the indications of rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis. Remsima is the first "similar" biotherapeutic product to be approved in Columbia and was developed by Celltrion in collaboration […]
back to top